EXPRS2 Stock Overview
Through its subsidiary, ExpreS2ion Biotechnologies ApS, researches and develops preventive and therapeutic vaccine products in the Nordics and internationally.
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 4/6 |
| Dividends | 0/6 |
ExpreS2ion Biotech Holding AB (publ) Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | SEK 0.86 |
| 52 Week High | SEK 5.80 |
| 52 Week Low | SEK 0.71 |
| Beta | 1.68 |
| 11 Month Change | -22.94% |
| 3 Month Change | -42.05% |
| 1 Year Change | -72.30% |
| 33 Year Change | -98.58% |
| 5 Year Change | -82.08% |
| Change since IPO | -84.78% |
Recent News & Updates
Shareholder Returns
| EXPRS2 | SE Biotechs | SE Market | |
|---|---|---|---|
| 7D | -0.6% | -5.9% | -6.7% |
| 1Y | -72.3% | 13.3% | 9.9% |
Return vs Industry: EXPRS2 underperformed the Swedish Biotechs industry which returned 18% over the past year.
Return vs Market: EXPRS2 underperformed the Swedish Market which returned 12.6% over the past year.
Price Volatility
| EXPRS2 volatility | |
|---|---|
| EXPRS2 Average Weekly Movement | 11.3% |
| Biotechs Industry Average Movement | 8.6% |
| Market Average Movement | 5.9% |
| 10% most volatile stocks in SE Market | 12.2% |
| 10% least volatile stocks in SE Market | 3.5% |
Stable Share Price: EXPRS2's share price has been volatile over the past 3 months.
Volatility Over Time: EXPRS2's weekly volatility has decreased from 35% to 11% over the past year, but is still higher than 75% of Swedish stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2015 | 18 | Bent Frandsen | www.expres2ionbio.com |
ExpreS2ion Biotech Holding AB (publ), through its subsidiary, ExpreS2ion Biotechnologies ApS, researches and develops preventive and therapeutic vaccine products in the Nordics and internationally. The company’s lead asset is ES2B-C001, a therapeutic vaccine for breast cancer that targets the human epidermal growth factor receptor 2 receptor. It is also developing ES2B-I002, a cytomegalovirus vaccine candidate to treat infectious diseases.
ExpreS2ion Biotech Holding AB (publ) Fundamentals Summary
| EXPRS2 fundamental statistics | |
|---|---|
| Market cap | SEK 71.92m |
| Earnings (TTM) | -SEK 77.95m |
| Revenue (TTM) | SEK 7.77m |
9.3x
P/S Ratio-0.9x
P/E RatioIs EXPRS2 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| EXPRS2 income statement (TTM) | |
|---|---|
| Revenue | SEK 7.77m |
| Cost of Revenue | SEK 3.32m |
| Gross Profit | SEK 4.44m |
| Other Expenses | SEK 82.39m |
| Earnings | -SEK 77.95m |
Last Reported Earnings
Mar 31, 2024
Next Earnings Date
Aug 15, 2024
| Earnings per share (EPS) | -0.93 |
| Gross Margin | 57.22% |
| Net Profit Margin | -1,003.55% |
| Debt/Equity Ratio | 0.6% |
How did EXPRS2 perform over the long term?
See historical performance and comparison